Why the study?
COVID-19 is associated with poor cardiac outcomes and increased cardiovascular risk, but long-term cardiovascular outcomes after exercise-based cardiac rehabilitation remain largely unknown.
Does exercise-based cardiac rehabilitation reduce long-term cardiovascular outcomes in adult COVID-19 survivors?
Does exercise-based cardiac rehabilitation reduce long-term cardiovascular outcomes in adult COVID-19 survivors?
Exercise-based cardiac rehabilitation is associated with significantly reduced risks of long-term cardiovascular events and mortality in COVID-19 survivors.
May support cardiac rehabilitation in COVID-19 survivors; hypothesis-generating pending randomized confirmation.
Objectives: Coronavirus disease 2019 (COVID-19) is associated with poor cardiac outcomes and an increased risk of long-term cardiovascular disease. Long-term cardiovascular outcomes among patients with COVID-19 after exercise-based cardiac rehabilitation remain largely unknown. This study aimed to investigate the long-term cardiovascular outcomes of COVID-19 survivors after exercise-based cardiac rehabilitation using real-world data. Materials and Methods: We analyzed the data from the US Collaborative Network of the TriNetX Research Database. Adults aged ≥18 years who were diagnosed with COVID-19 between 2020 and 2022 were enrolled in this study. The comparison comprised a cohort of patients receiving exercise-based cardiac rehabilitation and 1:1 propensity score-matched controls. Results: The exercise-based cardiac rehabilitation group was found to have lower risks of developing several long-term cardiovascular outcomes than the controls, such as mortality (hazard ratio [HR] = 0.75 [0.63-0.89]), stroke (HR = 0.81 [0.68-0.94]), myocardial infarction (HR = 0.75 [0.61-0.89]), ischemic cardiomyopathy (HR = 0.86 [0.75-0.99]), heart failure (HR = 0.73 [0.65-0.83]), and nonischemic cardiomyopathy (HR = 0.78 [0.63-0.92]). Conclusion: Among COVID-19 survivors, those undergoing cardiac rehabilitation had lower risks of cardiovascular outcomes, including mortality, stroke, myocardial infarction, ischemic cardiomyopathy, heart failure, and nonischemic cardiomyopathy, than those of controls.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: